Apotheek De Voldere
ActiveSummary
Apotheek De Voldere has been active since 2014 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €341,765 and a net result of €159,802. Equity has been stable since 2019 (±0.9% per year). Its solvency ranks better than 77% of 12,781 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 06-10-2014 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730and 2 others
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 30-09-2021
- Establishment unit
- 2.235.260.179 8750 Wingene, since 06-10-2014
- Financial year end
- 30 September
- Peppol
- Reachable since 03-12-2025
Board and ownership
- IDV INVESTDirector · since 01-10-2022 · permanent representative Ines De Voldere
- IDV INVEST100%2025 annual accounts of IDV INVEST
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
- Gross margin
- €321,424
- ▲ 63.0%
- Turnover
- ≈ €1.2m
- estimated
- Profit
- €159,802
- ▲ 105%
- Equity
- €341,765
- ▲ 30.5%
- Total assets
- €532,095
- ▲ 4.9%
- Employees on 30-09-2025
- 2
- =
Score breakdownraises riskSector: Retail trade (NACE 47)lowers riskLiquidity: current ratio 2.67, cash €189,694Equity €341,765 (64.2% of total assets)Founded in 2014Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 76% of them on solvency, 83% on liquidity, 96% on profitability and 79% on growth.
The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 8 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed Company renamed from APOTHEEK RYCKAERT NATHALIE to Apotheek De VoldereLegal-form conversion: from private limited company (pre-2019) to private limited company
- · Gazette deed 1 director appointed, 1 director resigningResignation: Nathalie Ryckaert (director) · Appointment: IDV INVEST (director) · Permanent representative: Ines De Voldere
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as Apotheek De Voldere: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €470,000 and €647,000, founded between 2014 and 2015.
| Company | Total assets | Gross margin |
|---|---|---|
| Apotheek De Voldere Wingene | €532,095 | €321,424 |
| Apotheek Klein-Sinaai Stekene | €544,832 | €347,493 |
| Apotheek Simons Boom | €646,845 | €285,227 |
| JELY PHARMA Incourt | €469,684 | €253,186 |
| APOTHEEK G. MOONEN Sint-Pieters-Leeuw | €625,839 | €278,206 |
| PHARMACIE THIRY ANNE Court-Saint-Etienne | €628,009 | €320,346 |
| Walemapotheek Mechelen | €491,415 | €242,339 |
Key facts about Apotheek De Voldere
- What is the company number of Apotheek De Voldere?
- The company number of Apotheek De Voldere is 0563.684.915. The VAT number is the same number with BE in front: BE 0563.684.915.
- Where is Apotheek De Voldere based?
- The registered office is at Kerkplein 24, 8750 Wingene.Company details
- What does Apotheek De Voldere do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of Apotheek De Voldere?
- The legal form of Apotheek De Voldere is Private limited company (BV).
- When was Apotheek De Voldere founded?
- Apotheek De Voldere was founded on 06-10-2014.
- Is Apotheek De Voldere still active?
- Yes, Apotheek De Voldere is an active enterprise in the KBO register.
- How many employees does Apotheek De Voldere have?
- Apotheek De Voldere had an average of 1.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Apotheek De Voldere fall under?
- In its 30-09-2021 annual accounts, Apotheek De Voldere states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of Apotheek De Voldere?
- The turnover in financial year 2025 is ≈ €1.2m. This figure is estimated from the gross margin of €321,424 and 47 comparable companies (NACE 477). It probably lies between €910,000 and €1.9m.
- Is Apotheek De Voldere profitable?
- In financial year 2025, Apotheek De Voldere made a profit of €159,802.
- Where can I find the annual accounts of Apotheek De Voldere?
- Apotheek De Voldere filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Apotheek De Voldere due?
- Apotheek De Voldere must file the annual accounts for financial year 2026 by 30-04-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.